• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群靶向治疗在非酒精性脂肪性肝病中的作用:一项系统评价和网状Meta分析

The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.

作者信息

Song Yijia, Liu Sutong, Zhang Lihui, Zhao Wenxia, Qin Yuanmei, Liu Minghao

机构信息

Department of Spleen, Stomach, Hepatobiliary Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.

The First Clinical Medical School of Henan University of Chinese Medicine, Zhengzhou, China.

出版信息

Front Nutr. 2025 Jan 6;11:1470185. doi: 10.3389/fnut.2024.1470185. eCollection 2024.

DOI:10.3389/fnut.2024.1470185
PMID:39834471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11743284/
Abstract

BACKGROUND

The incidence of NAFLD is increasing. Preclinical evidences indicate that modulation of the gut microbiome could be a promising target in nonalcoholic fatty liver disease.

METHOD

A systematic review and network meta-analysis was conducted to compare the effect of probiotics, synbiotics, prebiotics, fecal microbiota transplant, and antibiotics on the liver-enzyme, metabolic effects and liver-specific in patients with NAFLD. The randomized controlled trails (RCTs), limited to English language were searched from database such as Pubmed, Embase, Web of science and Cochrane Library from inception to November 2024. Review Manager 5.3 was used to to draw a Cochrane bias risk. Inconsistency test and publication-bias were assessed by Stata 14.0. Random effect model was used to assemble direct and indirect evidences. The effects of the intervention were presented as mean differences with 95% confidence interval.

RESULTS

A total of 1921 patients from 37 RCTs were eventually included in our study. 23 RCTs evaluated probiotics, 10 RCTs evaluated synbiotics, 4 RCTs evaluated prebiotics, 3 RCTs evaluated FMT and one RCT evaluated antibiotics. Probiotics and synbiotics were associated with a significantly reduction in alanine aminotransferase [ALT, (MD: -5.09; 95%CI: -9.79, -0.39), (MD: -7.38, 95CI%: -11.94, -2.82)] and liver stiffness measurement by elastograph [LSM, (MD: -0.37;95%CI: -0.49, -0.25), (MD: -1.00;95%CI: -1.59, -0.41)]. In addition to, synbiotics was superior to probiotics in reducing LSM. Synbiotics was associated with a significant reduction of Controlled Attenuation Parameter [CAP, (MD: -39.34; 95%CI: -74.73, -3.95)]. Both probiotics and synbiotics were associated with a significant reduction of aspartate transaminase [AST, (MD: -7.81; 95%CI: -15.49, -0.12), (MD: -13.32; 95%CI: -23, -3.64)]. Probiotics and Allogenic FMT was associated with a significant reduction of Homeostatic Model Assessment for Insulin Resistance [HOMA-IR, (MD: -0.7, 95%CI: -1.26, -0.15), (MD: -1.8, 95%CI: -3.53, - 0.07)]. Probiotics was associated with a significant reduction of body mass index [BMI, MD: -1.84, 95%CI: -3.35, -0.33].

CONCLUSION

The supplement of synbiotics and probiotics maybe a promising way to improve liver-enzyme, LSM, and steatosis in patients with NAFLD. More randomized controlled trials are needed to determine the efficacy of FMT and antibiotics on NAFLD. And the incidence of adverse events of MTTs should be further explored.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, CRD42023450093.

摘要

背景

非酒精性脂肪性肝病(NAFLD)的发病率正在上升。临床前证据表明,调节肠道微生物群可能是治疗非酒精性脂肪性肝病的一个有前景的靶点。

方法

进行了一项系统评价和网络荟萃分析,以比较益生菌、合生元、益生元、粪便微生物群移植和抗生素对NAFLD患者肝酶、代谢效应和肝脏特异性指标的影响。从创刊至2024年11月,在PubMed、Embase、Web of science和Cochrane图书馆等数据库中检索仅限于英文的随机对照试验(RCT)。使用Review Manager 5.3绘制Cochrane偏倚风险图。通过Stata 14.0评估异质性检验和发表偏倚。采用随机效应模型汇总直接和间接证据。干预效果以平均差值和95%置信区间表示。

结果

本研究最终纳入了来自37项RCT的1921例患者。23项RCT评估了益生菌,10项RCT评估了合生元,4项RCT评估了益生元,3项RCT评估了粪便微生物群移植,1项RCT评估了抗生素。益生菌和合生元与丙氨酸氨基转移酶[ALT,(平均差值:-5.09;95%置信区间:-9.79,-0.39),(平均差值:-7.38,95%置信区间:-11.94,-2.82)]和通过弹性成像测量的肝脏硬度[LSM,(平均差值:-0.37;95%置信区间:-0.49,-0.25),(平均差值:-1.00;95%置信区间:-1.59,-0.41)]的显著降低相关。此外,合生元在降低LSM方面优于益生菌。合生元与受控衰减参数[CAP,(平均差值:-39.34;95%置信区间:-74.73,-3.95)]的显著降低相关。益生菌和合生元均与天冬氨酸转氨酶[AST,(平均差值:-7.81;95%置信区间:-15.49,-0.12),(平均差值:-13.32;95%置信区间:-23,-3.64)]的显著降低相关。益生菌和同种异体粪便微生物群移植与胰岛素抵抗稳态模型评估[HOMA-IR,(平均差值:-0.7,95%置信区间:-1.26,-0.15),(平均差值:-1.8,95%置信区间:-3.53,-0.07)]的显著降低相关。益生菌与体重指数[BMI,平均差值:-1.84,95%置信区间:-3.35,-0.33]的显著降低相关。

结论

补充合生元和益生菌可能是改善NAFLD患者肝酶、LSM和脂肪变性的一种有前景的方法。需要更多的随机对照试验来确定粪便微生物群移植和抗生素对NAFLD的疗效。并且应进一步探索MTTs不良事件的发生率。

系统评价注册

https://www.crd.york.ac.uk/prospero/,CRD42023450093。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/468aa3e14e82/fnut-11-1470185-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/882a6205b190/fnut-11-1470185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/33e74430e246/fnut-11-1470185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/eb094c452e69/fnut-11-1470185-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/2119defb9083/fnut-11-1470185-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/b6e34eb1daf3/fnut-11-1470185-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/468aa3e14e82/fnut-11-1470185-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/882a6205b190/fnut-11-1470185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/33e74430e246/fnut-11-1470185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/eb094c452e69/fnut-11-1470185-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/2119defb9083/fnut-11-1470185-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/b6e34eb1daf3/fnut-11-1470185-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69d4/11743284/468aa3e14e82/fnut-11-1470185-g006.jpg

相似文献

1
The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.肠道微生物群靶向治疗在非酒精性脂肪性肝病中的作用:一项系统评价和网状Meta分析
Front Nutr. 2025 Jan 6;11:1470185. doi: 10.3389/fnut.2024.1470185. eCollection 2024.
2
Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.非酒精性脂肪性肝病的肠道微生物组靶向治疗:系统评价、荟萃分析和荟萃回归。
Am J Clin Nutr. 2019 Jul 1;110(1):139-149. doi: 10.1093/ajcn/nqz042.
3
Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.合生元、益生菌和益生元对非酒精性脂肪性肝病患者肝脏酶的影响:一项系统评价和网状Meta分析
Front Nutr. 2022 May 20;9:880014. doi: 10.3389/fnut.2022.880014. eCollection 2022.
4
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis.肠道微生物组靶向治疗对非酒精性脂肪性肝病患者肝酶的影响:伞式荟萃分析。
Nutr Rev. 2024 May 10;82(6):815-830. doi: 10.1093/nutrit/nuad086.
5
Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.益生菌、益生元及合生元在非酒精性脂肪性肝病中的应用:一项系统评价与荟萃分析
J Gastroenterol Hepatol. 2023 Oct;38(10):1682-1694. doi: 10.1111/jgh.16256. Epub 2023 Jul 6.
6
The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis.益生菌/益生元/合生菌在非酒精性脂肪性肝病患者能量代谢生物标志物中的潜在作用:系统评价和荟萃分析。
Front Public Health. 2022 Jul 25;10:862266. doi: 10.3389/fpubh.2022.862266. eCollection 2022.
7
Functional foods and dietary supplements in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.功能性食品和膳食补充剂在非酒精性脂肪性肝病管理中的应用:一项系统评价和荟萃分析。
Front Nutr. 2023 Feb 14;10:1014010. doi: 10.3389/fnut.2023.1014010. eCollection 2023.
8
Anti-inflammatory effects of probiotics and synbiotics on patients with non-alcoholic fatty liver disease: An umbrella study on meta-analyses.益生菌和合生菌对非酒精性脂肪性肝病患者的抗炎作用:荟萃分析的伞状研究。
Clin Nutr ESPEN. 2023 Oct;57:475-486. doi: 10.1016/j.clnesp.2023.07.087. Epub 2023 Jul 31.
9
Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.益生菌和合生菌治疗非酒精性脂肪性肝病的疗效:Meta 分析。
Dig Dis Sci. 2019 Dec;64(12):3402-3412. doi: 10.1007/s10620-019-05699-z. Epub 2019 Jun 15.
10
The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis.益生菌和合生元疗法在非酒精性脂肪性肝病患者转氨酶水平和炎症标志物方面的潜在作用——一项系统评价和荟萃分析
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):703-715. doi: 10.1097/MEG.0000000000001371.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病(MASLD):肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Therapeutic Potential of Probiotics in Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Review.益生菌在代谢功能障碍相关脂肪性肝炎中的治疗潜力:一项综述
Microorganisms. 2025 Aug 14;13(8):1894. doi: 10.3390/microorganisms13081894.

本文引用的文献

1
Retraction Note: The Effect of Dexmedetomidine and Esmolol on Early Postoperative Cognitive Dysfunction After Middle Ear Surgery Under Hypotensive Technique: A Comparative, Randomized, Double-blind Study.撤稿说明:右美托咪定和艾司洛尔对低血压技术下中耳手术后早期认知功能障碍的影响:一项比较、随机、双盲研究。
Anesth Pain Med. 2024 Jun 2;14(3):e149456. doi: 10.5812/aapm.149456. eCollection 2024 Jun.
2
The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt.埃及开罗一家三级医院诊所的患者中,益生菌补充对非酒精性脂肪性肝病(NAFLD)纤维化评分的影响。
BMC Gastroenterol. 2024 Oct 8;24(1):354. doi: 10.1186/s12876-024-03424-3.
3
Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial.
益生菌治疗非酒精性脂肪性肝病(NAFLD)患者的随机试验。
Nutrients. 2024 May 22;16(11):1571. doi: 10.3390/nu16111571.
4
Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.基于 FibroTouch 分析非酒精性脂肪性肝病患者的临床特征及识别危险因素
Sci Rep. 2023 Sep 8;13(1):14812. doi: 10.1038/s41598-023-41596-2.
5
Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?肌肉减少症,多种疾病共有的一种状态:我们能否缓解或延缓其进展?
Intern Emerg Med. 2023 Oct;18(7):1887-1895. doi: 10.1007/s11739-023-03339-z. Epub 2023 Jul 25.
6
Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.短双歧杆菌产生的醋酸盐可抑制非酒精性脂肪性肝病相关肝细胞癌。
J Hepatol. 2023 Dec;79(6):1352-1365. doi: 10.1016/j.jhep.2023.07.005. Epub 2023 Jul 17.
7
Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.益生菌、益生元及合生元在非酒精性脂肪性肝病中的应用:一项系统评价与荟萃分析
J Gastroenterol Hepatol. 2023 Oct;38(10):1682-1694. doi: 10.1111/jgh.16256. Epub 2023 Jul 6.
8
and Prevent NAFLD by Regulating FXR Expression and Gut Microbiota.通过调节法尼醇X受体(FXR)表达和肠道微生物群预防非酒精性脂肪性肝病(NAFLD)
J Clin Transl Hepatol. 2023 Aug 28;11(4):763-776. doi: 10.14218/JCTH.2022.00415. Epub 2023 Feb 22.
9
The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis.合生元对非酒精性脂肪性肝病患者的影响:一项系统评价和荟萃分析。
Therap Adv Gastroenterol. 2023 Jun 22;16:17562848231174299. doi: 10.1177/17562848231174299. eCollection 2023.
10
Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial.益生菌补充剂对非酒精性脂肪性肝炎患者肝纤维化和微生物群特征的影响:一项随机对照试验。
J Nutr. 2023 Jul;153(7):1984-1993. doi: 10.1016/j.tjnut.2023.05.019. Epub 2023 May 22.